Re-induction chemotherapy using FLAG–mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates
| Autor: | Khalid Al qawasmeh, Arif Alam, Inaam Bashir Hassan, Kristensen Js |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent United Arab Emirates Single Center Gastroenterology Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Recurrence hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Survival rate Aged Mitoxantrone Acute leukemia Leukemia business.industry Cytarabine Induction chemotherapy Induction Chemotherapy Hematology Middle Aged Survival Rate Transplantation Regimen 030220 oncology & carcinogenesis Acute Disease FLAG (chemotherapy) Female business Vidarabine 030215 immunology medicine.drug |
| Zdroj: | International Journal of Hematology. 108:390-401 |
| ISSN: | 1865-3774 0925-5710 |
| DOI: | 10.1007/s12185-018-2478-3 |
| Popis: | We studied the outcome of 47 adult patients with relapsed acute leukaemia (AML = 25 and ALL = 22) treated with FLAG-mitoxantrone regimen. Median time to relapse was 10.7 months (range 1.9-27.7). Complete remission (CR2) was 60.1% which was significantly more frequent in ALL compared to AML (P = 0.049). WBC count 1 year were significantly predictor for CR2 in AML (P = 0.005 for both). Induction death was significantly higher in ALL compared to AML (P = 0.039). Median follow-up was 4.0 months (0.9-119.8) for AML and 2.1 months (range 0.6-118.1) for ALL. Nine patients underwent allogeneic stem-cell transplantation (allo-SCT). Estimated overall survival (OS) at 12 and 18 months was 60.5 and 34.6%, respectively, for AML, and 39.9 and 29.9%, respectively, for ALL. For AML patients failure to achieve CR, WBC count at initial diagnosis > 5 × 109/L and poor cytogenetic risk group was significant predictors of poor OS (P = 0.010, P = 0.025, and P = 0.015, respectively). For ALL patients failure to achieve of CR, WBC count at relapse |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink